"With the third positive independent safety review complete we are confident of the suitability of Xanamem for longer-term treatment. Xanamem has the potential to be a game-changer for Alzheimer’s disease given its potential product profile as a safe and effective oral medication with the ability to slow disease course progression significantly more than any approved therapy." Dr Steven Gourlay, CEO